Cholesterol Is Essential. Atherosclerosis Is the Problem.
Maybe the better question isn’t, “How low can we make the cholesterol number?”
Maybe it’s: “What is this person’s actual cardiovascular risk—and what is driving it?”
Let’s start with something that often gets lost in the cholesterol conversation:
Your body needs cholesterol.
Not a little bit.
Cholesterol is built into cell membranes throughout the body. It is used to make steroid hormones. It helps produce bile acids. It is part of the pathway used to produce vitamin D.
Cortisol starts downstream from cholesterol.
Aldosterone starts downstream from cholesterol.
Testosterone. Estrogen. Progesterone.
All connected to cholesterol biology.
Cholesterol isn’t a toxin your body accidentally forgot to get rid of.
It is essential human biology.Cholesterol Sits at the Center of Important Biology
Cell Membranes
Cholesterol contributes to membrane structure, stability, fluidity, and cellular signaling.
Hormones
Cholesterol is the precursor for adrenal and sex steroid hormones.
Vitamin D
Cholesterol-derived molecules participate in the pathway that ultimately produces vitamin D.
Bile Acids
Cholesterol is converted into bile acids that help digest and absorb dietary fat.
But Here’s the Important Distinction
Cholesterol does not dissolve freely in blood.
It has to be transported inside particles called lipoproteins.
LDL is one of those transport systems.
And each atherogenic particle carries a structural protein called apolipoprotein B—or ApoB.
Think of Cholesterol as Cargo
Cholesterol is something the body needs to move between tissues.
Measuring LDL-C tells us roughly how much cholesterol is being carried inside LDL particles.
Think of ApoB Particles as Trucks
ApoB provides another way of estimating the number of atherogenic particles circulating through the bloodstream.
Two people can have similar LDL-C while carrying that cholesterol in different numbers of particles.
Essential Does Not Mean “More Is Always Better”
The fact that cholesterol is essential to human physiology does not make elevated concentrations of circulating atherogenic lipoproteins harmless.
Genetic studies, epidemiology, and randomized clinical trials provide strong evidence that prolonged exposure to ApoB-containing lipoproteins contributes causally to atherosclerosis.
So Is It the Cholesterol—or the Environment?
This is where the cholesterol debate often becomes unnecessarily binary.
One side says:
“LDL is the entire problem.”
The other says:
“LDL doesn’t matter. It’s only inflammation and metabolic health.”
Human biology is more complicated than either statement.
The number and duration of exposure to atherogenic particles matters.
But so does the biological environment those particles are traveling through.
Context Doesn’t Make ApoB Disappear
A metabolically healthy person with elevated ApoB may have a different absolute risk than a smoker with diabetes, hypertension, kidney disease, and the same ApoB.
But better metabolic health does not make long-term exposure to atherogenic particles irrelevant.
What Does a Standard Lipid Panel Actually Tell You?
The cholesterol contained across several circulating lipoprotein classes.
The amount of cholesterol carried within LDL particles—not necessarily the particle number itself.
Cholesterol carried within HDL particles. It is a risk marker but should not be interpreted as a simple protective antidote to LDL.
Circulating fats influenced by metabolic health, genetics, alcohol, diet, and recent food intake.
A lipid panel is valuable. It is not a complete cardiovascular autobiography.
Your Lipid Panel Is a Snapshot in Time
Blood biomarkers are dynamic.
Diet changes. Weight changes. Alcohol intake changes. Exercise changes. Illness changes. Medications change. Metabolic health changes.
So yes—a lipid panel represents what was happening biologically around the time it was measured.
What Recent Food Can Change
Triglycerides are the standard lipid measurement most affected by recent eating.
A particularly large or high-fat meal can produce a more noticeable post-meal triglyceride response.
What We Shouldn’t Say
A meal the night before does not usually make the entire lipid panel meaningless.
Modern guidelines accept nonfasting lipid testing for many routine cardiovascular-risk assessments.
In large studies, habitual meals generally caused only modest average changes in total cholesterol and LDL-C.
Triglycerides changed more.
ApoB and Lp(a) are much less affected by whether someone recently ate.
One Result Is a Data Point. Trends Are More Informative.
An unexpected result can often be repeated under consistent conditions before making a major long-term decision—particularly when the result does not fit the rest of the clinical picture.
Sometimes the Standard Panel Doesn’t Tell the Whole Story
Interestingly, This Is Now Mainstream Cardiology
The 2026 ACC/AHA dyslipidemia guideline incorporates overall cardiovascular risk, PREVENT risk estimates, ApoB, Lp(a), risk enhancers, and selective coronary calcium testing when making treatment decisions.
In other words: context matters.
So Are Statins Really the Answer?
Statins inhibit an enzyme called HMG-CoA reductase in the cholesterol-synthesis pathway.
The liver responds by increasing LDL receptors on its surface, which helps remove more circulating LDL particles from the blood.
A Statin Does Not Simply “Remove Cholesterol From Your Body”
Cholesterol metabolism is highly regulated. The major therapeutic effect of statins is to reduce exposure of the arterial system to circulating atherogenic lipoproteins.
We Should Also Be Honest About Something Else: Statins Work
Randomized clinical trials involving very large numbers of people have demonstrated that lowering LDL with statin therapy reduces major cardiovascular events.
That effect is especially important when someone’s baseline risk is already high.
Someone who has already had a myocardial infarction, stroke, or established atherosclerotic disease is having a completely different risk-benefit conversation than a healthy younger adult with one mildly abnormal laboratory value.
Higher Baseline Risk
When the probability of a cardiovascular event is high, lowering atherogenic lipoprotein exposure can create a meaningful absolute reduction in risk.
Lower or Uncertain Risk
When absolute risk is lower or the decision is uncertain, it becomes increasingly important to understand the entire risk profile rather than treating one laboratory value in isolation.
The question shouldn’t be, “Are statins good or bad?”
The better question is: what is the expected benefit for this person?What About Statin Side Effects?
Statins are medications.
Medications can produce adverse effects.
Muscle symptoms receive the most attention, and some people genuinely experience statin-associated muscle symptoms.
Statins can also modestly increase diabetes risk in susceptible patients and can produce abnormalities in liver enzymes.
Severe muscle injury such as rhabdomyolysis is possible but rare.
Muscle Symptoms
Real in some people, but blinded trials show the excess caused by statins is considerably smaller than the total number of muscle complaints reported while people happen to be taking them.
Blood Glucose
Statins can slightly increase the likelihood of newly diagnosed diabetes, particularly in people already metabolically predisposed.
Liver Enzymes
Mild laboratory elevations occur somewhat more frequently with statin therapy. Serious liver injury remains uncommon.
Cognition
Large randomized analyses have not demonstrated convincing evidence that statins routinely cause cognitive impairment or dementia.
A Long Side-Effect List Does Not Tell You the Probability
A symptom appearing in someone taking a medication is not automatically caused by that medication.
Large blinded randomized trials are particularly useful because they allow us to compare symptoms against people taking placebo.
But “Statins Are Safe” Shouldn’t End the Conversation Either
An intervention should provide enough expected benefit to justify its inconvenience, cost, uncertainty, and potential adverse effects for the individual taking it.
My Problem Is Not With Lowering LDL
Imagine two patients both have an LDL-C of 155 mg/dL.
Patient A is physically active, normotensive, nonsmoking, metabolically healthy, with low triglycerides, no diabetes, no chronic kidney disease, reassuring family history, and no evidence of coronary calcification.
Patient B smokes, has hypertension, diabetes, high triglycerides, chronic kidney disease, elevated ApoB, and a strong family history of premature coronary disease.
Same LDL-C.
Very different cardiovascular conversation.
Treat the risk. Don’t just treat the red number on the laboratory report.
Cardiovascular Risk Usually Doesn’t Arrive Alone
When someone develops significant metabolic dysfunction, it is often not one biomarker that changes.
We may see some combination of:
That pattern is telling a bigger biological story than one isolated cholesterol value.
Biomarkers Are Clues
They are most useful when they help us understand the physiology occurring underneath them.
What Would a Personalized Cholesterol Conversation Look Like?
Verify the Pattern
Review previous lipid results and repeat unexpected values when appropriate.
Assess Total Risk
Consider age, blood pressure, smoking, diabetes, kidney health, family history, and other relevant risk factors.
Clarify When Needed
ApoB, Lp(a), non-HDL-C, or selective CAC imaging can sometimes add useful information when the decision remains uncertain.
Choose the Lever
Nutrition, weight loss, exercise, smoking cessation, blood pressure treatment, statins, or another lipid-lowering strategy may each be appropriate depending on the individual.
Cholesterol Is a Perfect Example of Why Personalized Medicine Matters
“Cholesterol is bad” is too simple.
Cholesterol is essential to life.
“LDL doesn’t matter” is also too simple.
Long-term exposure to ApoB-containing lipoproteins plays a causal role in atherosclerosis.
“Everyone with an elevated LDL needs the same treatment” is too simple.
Absolute risk, age, comorbidities, genetics, metabolic health, existing plaque, patient preferences, and treatment tolerance all matter.
Don’t Optimize the Lab. Optimize the Person.
Cholesterol is one component of cardiovascular biology. The goal is not to win an argument about LDL or statins. The goal is to reduce the patient’s lifetime risk of heart attack, stroke, disability, and premature death while preserving overall health.
Understand the biology. Understand the risk. Then choose the lever.Maybe the Better Question Isn’t “Do I Need a Statin?”
Start with:
What is my actual cardiovascular risk, what is driving that risk, and which intervention gives me the best risk-to-benefit tradeoff?
For some people, the answer will absolutely include a statin.
For others, the immediate priority may be smoking cessation, blood pressure, body composition, exercise, sleep, nutrition, diabetes treatment, or further risk clarification.
Often it will be several of those things at once.
That is what happens when we stop treating health as one isolated laboratory value and start looking at the system.
One Number Is Not a Wellness Strategy
Use the lipid panel. Respect what it tells you. Understand what it cannot tell you. Then put it into the context of the entire patient.
The target isn’t cholesterol. The target is cardiovascular risk.Want to Better Understand Your Cardiovascular Risk?
A personalized wellness consultation can review your goals, lipid history, metabolic health, lifestyle, medications, risk factors, and available options so you can have a more informed conversation about what your numbers actually mean.
Book a Wellness ConsultationAbout the Author
Selected Scientific References
Overview of cholesterol’s roles in cell membranes and its use as a precursor for steroid hormones, vitamin D, and bile acids.
View on PubMed →
Consensus review of genetic, epidemiologic, Mendelian-randomization, and randomized-trial evidence establishing LDL and ApoB-containing lipoproteins as causal contributors to atherosclerotic cardiovascular disease.
View on PubMed →
Review of the biological mechanisms linking retention of ApoB-containing lipoproteins to the initiation and progression of atherosclerosis.
View on PubMed →
Current U.S. recommendations incorporating PREVENT risk calculation, LDL-C and non-HDL-C goals, ApoB, Lp(a), risk enhancers, and selective coronary artery calcium assessment.
View 2026 Guideline →
Patient and clinician education describing ApoB as a marker of circulating atherogenic particle number.
View AHA Information →
Consensus review comparing fasting and nonfasting lipid testing, including typical post-meal changes in triglycerides, LDL-C, ApoB, and Lp(a).
View Consensus Statement →
Large randomized-trial meta-analyses demonstrating reduction in major vascular events with statin-mediated LDL lowering.
View on PubMed →
Individual-participant meta-analysis examining muscle symptoms in large double-blind randomized statin trials.
View on PubMed →
Large individual-participant analysis of adverse events attributed to statins in double-blind randomized controlled trials.
View on PubMed →